ROPOFOL-RELATED infusion syndrome has more commonly been recognized and reported to occur in the setting of long-term sedation of patients in the ICU. It is characterized by metabolic acidosis, unexplained cardiac failure, rhabdomyolysis, and renal failure. 19 Authors of recent reports have discussed the occurrence of this syndrome in the short term, usually high-dose administrations of propofol, particularly during long procedures that require sedation.
referred to our institution for consultation concerning a giant intracranial aneurysm. She had initially presented in the summer of 2004 with diplopia and strabismus. A magnetic resonance image of the brain at that time had revealed unremarkable findings. Approximately 1 year later she was seen by a neuroophthalmologist, and repeated magnetic resonance imaging of the brain revealed an intracranial aneurysm. Interventional radiologists at another institution had previously made three attempts at embolization, which were complicated by coil prolapse into the parent vessel.
Operation. The patient was pretreated with aspirin and clopidogrel for 5 days before the procedure. The plan first entailed a 20-minute BOT of the left ICA and, if the procedure was successfully tolerated, subsequent stent-assisted embolization was to be performed after the induction of propofol anesthesia. Anesthesia was induced with boluses of 50 mg propofol/25 g fentanyl and 30 mg propofol/50 g fentanyl over the 1st hour. Anesthesia was maintained with 200 g/kg/min of propofol infusion and 1 g/kg/hr of fentanyl.
A 19 ϫ 22 ϫ 17-mm aneurysm was identified on the initial left ICA angiogram (Fig. 1A) . The patient tolerated a 20-minute left ICA BOT well; excellent collateral flow was noted by direct evaluation through somatosensory evoked potential, motor evoked potential, and electroencephalographic monitoring. Stent-assisted embolization of the aneurysm was undertaken (Fig. 1B) , and three bioactive coils were placed. The procedure was complicated by a stretched coil that had dislodged into the lumen of the ICA. This coil was snared successfully, but the maneuver substantially increased the procedure time. Deployment of 22 progressively smaller coils accomplished adequate occlusion of the aneurysm (Fig. 1C) .
Near the 5-hour mark, the patient developed anion gap (Ͼ 12 mmol/L) metabolic acidosis (pH 7.28, PaCO 2 41 mm Hg, HCO 3 Ϫ 18 mmol/L), which persisted until the end of the procedure. The arterial blood gas measurements obtained 30 minutes before and after completion of the procedure were the following, respectively: pH 7. 18 Ϫ was added to the normal saline drip. Following the procedure, the patient was treated with a regimen of 81 mg aspirin and 37.5 mg clopidogrel daily, along with an abciximab intravenous drip 4 ml/ hour for 12 hours.
Postoperatively the creatine phosphokinase, lactate dehydrogenase, and lactate values were 263 U/L (normal range 22-269 U/L), 179 U/L (normal range 91-180 U/L), and 1.1 mmol/L (normal range 0.7-2.1 U/L), respectively; the blood urea nitrogen and creatinine levels were 11 and 0.6 mg/dl, respectively. In the PICU, the patient's blood pressure dropped to 60/30 mm Hg and her heart rate increased to 150 bpm. She remained tachycardic and underwent aggressive fluid resuscitation with 5% albumin, vasopressors, and 5 mg dexamethasone every 8 hours for 5 days.
On Day 3 her salicylate (Ͻ 4.0 mg/dl) and ammonia (28 mmol/L) levels were within normal limits, and the acidosis significantly improved. Her creatine phosphokinase level increased to 473 to 591 U/L, with a creatine phosphokinase 2-myoglobin level of 20.7 ng/ml (normal level Ͻ 5 ng/ml) and a relative index of 3.5 (normal index Ͻ 2.5)-a strong indication of myocardial injury. Her systolic blood pressure was maintained in the range of 100 to 120 mm Hg, and her condition stabilized to the point that vasopressor support was removed on postoperative Day 4.
Postoperative Course. Pharmacological sedation in the PICU was maintained, first with midazolam 50 mg/50 ml and fentanyl 1000 g/50 ml, and then continued with fentanyl 1000 g/50 ml, which was weaned on Day 4. The patient subsequently underwent extubation, and she experienced progressive improvement. She was discharged from the hospital on Day 7 on a regimen of aspirin and clopidogrel.
Discussion
Propofol infusion syndrome has been reported as a combination of metabolic acidosis (usually lactic acidosis), hypotension, bradycardia or bradycardic dysrhythmia, myoglobinuria, and renal failure. Electrocardiography changes, reported to occur in precordial leads V1 to V3 (downsloping ST segment elevation), can predict sudden death in propofol infusion syndrome. 17 This condition is more frequently reported to occur after prolonged administration of propofol in critically ill patients in the ICU who require sedation. 16 Authors of more recent reports have described propofol syndrome occurring after short-term high-dose administration of propofol during long procedures requiring sedation, particularly in adults. 4 The metabolic acidosis in our case represents an early sign of propofol infusion syndrome. 6 During the procedure, the patient's pCO 2 was maintained at 32 mm Hg and her respiratory rate at 11 breaths/minute. To our knowledge no cases of systemic metabolic acidosis have been reported during cerebral angiography with or without a BOT, with or without embolization. This patient did not have juvenile diabetes, was no less active than her peers, and was in otherwise good health.
Propofol is considered a safe drug for long-term infusion in patients who have suffered brain trauma, 8 and it is routinely used in pediatric and adult patients for intraoperative sedation. The distribution and clearance of propofol in 53 children between the ages of 3 and 12 years who received propofol injectable emulsion for periods of approximately 1 to 2 hours were similar to that in adults. 12 As such, adults and children alike can be at risk for propofol infusion syndrome. However, this syndrome does not occur with every long-term or high-dose administration of propofol.
The patient in our case underwent a procedure for which a total of 80 mg propofol was administered during a 20-minute BOT. Motor and somatosensory evoked potentials were monitored and electroencephalography was performed for cerebrovascular accident prediction. In addition, the high-dose administration of 200 g/kg/min of propofol for the remaining 4 hours of the procedure may have played a significant role in triggering an early propofol infusion syndrome. The total dosage of propofol was 992 mg over 8 hours, which is a significant amount for a 3-year-old child. The median induction dose of propofol for a surgical procedure in a child her size and age is 2.5 mg/kg (range 1-3.6 mg/kg) with a median maintenance dose of 188 g/kg/min (range 12-1041 g/kg/min) for 69 minutes (range 23-374 minutes). 12 However, to avoid development of propofol infusion syndrome a maintenance dose of no more than 75 g/kg/min is suggested.
14 In 2001 the Food and Drug Administration issued a safety alert that there may be important concerns when propofol injectable emulsion is used for sedation in patients in the PICU. 5 They also reminded healthcare professionals that propofol is not approved in the US for sedation in the PICU. 5 To prevent propofol infusion syndrome, Baker and Naguib 1 suggested that the infusion amount be less than 75 g/kg/min for sedation of critically ill children and that the duration of infusion be limited to 24 hours.
Koch et al. 9 described the case of a 5-year-old patient who had undergone endovascular embolization for an arteriovenous malformation and was required to remain sedated for at least 24 hours with propofol at a rate of 15 mg/kg/hr. This patient experienced reversal of lactic acidosis following tapering to 6 mg/kg/hr and termination of propofol. Holzki et al. 7 reported the case of a 3-year-old patient who received 20 mg/kg/hr of propofol over a 15-hour period, after which the patient developed combined respiratory and metabolic acidosis. This resolved after cessation of propofol; however, the infusion was restarted at 4 mg/kg/hr, and the patient developed intractable bradycardia and later died. 7 Recent reports of propofol infusion syndrome with short-term highdose propofol infusion underscore the importance of extreme caution with a drug that had previously been considered safe. 8 Metabolism of propofol may be the underlying cause of propofol infusion syndrome; high-dose infusion is associated with hypertriglyceridemia and cardiac failure. 2 Wolf et al. 20 proposed impaired fatty acid oxidation as the probable cause of this syndrome. The authors ascribed the condition to the disruption of fatty acid oxidation caused by impaired entry of long-chain acylcarnitine esters into the mitochondria and failure of the mitochondrial respiratory chain at complex 11, resulting in uncoupling of the respiratory chain. 20 It may be that certain individuals are more sensitive to propofol, possibly by inhibition of cytochrome c-oxidase, or poor metabolization such as that seen in slow acetylators of isoniazid and hydralazine. 15 Propofol is cleared predominantly via direct glucuronidation, although a substantial amount is metabolized through the microsomal cytochrome P450 (2B6) system. 3 Propofol inhibits cytochrome P450 1A2, 2C9, 2D6, and 3A4, 11 particularly affecting testosterone 11 and ropivacaine 13 metabolism. This degree of inhibition is relatively low, and the clinical significance has yet to be established. 11 There are few reports of possible drugdrug interactions between propofol and alfentanil 18 or warfarin, 10 and in vivo studies in individuals with possible defective enzymes have yet to be reported.
Conclusions
This is the case of a 3-year-old child developing early signs of propofol-related infusion syndrome characterized by metabolic acidosis and hypotension. The patient received more than the suggested dose of 75 g/kg/min, 14 and the case illustrates that this syndrome can occur during long procedures requiring high-dose propofol sedation. Inhibition of fatty acid metabolism has been proposed as the likely cause. Physicians and caregivers should be cognizant of unknown differences of propofol metabolism in patients. The developments of metabolic acidosis, bradycardia, or hypotension during propofol infusion are early signs of propofol-related infusion syndrome and should be heeded as such.
